FACULTY
 

	Hemal Gada, MD, MBA UPMC Pinnacle Harrisburg, PA		Helge Möllmann, MD St. Johannes Hospital Dortmund Dortmand, Germany
	Kendra J. Grubb, MD, MHA Emory University Atlanta, GA		Thomas Pilgrim, MD  Bern University Hospital  Berne, Switzerland

AGENDA

• ACURATE neo2: Features and Benefits for Optimized TAVR: Prof. Helge Möllmann
   
• Lessons from the SCOPE I Study and the ACURATE neo2 Body of Evidence: Prof. Thomas Pilgrim
   
• Real-World Experience of the LOTUS Edge Valve: Dr. Hemal Gada
   
• Mitigating a Devastating Outcome: SENTINEL CPS in TAVR: Dr. Kendra Grubb

^{This sponsored message does not reflect the opinion or views of TCTMD or of The Cardiovascular Research Foundation.}

^{In the U.S. the ACURATE neo/ACURATE neo2 Valve System is an investigational device and restricted under federal law to investigational use only. Not available for sale.}

^{ACURATE neo CE mark received 2014. Information for the ACURATE Valve System is for use in countries with applicable product registrations. Indications, contraindications, warnings and instructions for use can be found in the product labeling supplied with each device.  Information not intended for use in France.}

This program was supported by: